Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02979613 · ClinicalTrials.gov registry record · Phase 3

Study to Evaluate Efficacy and Safety of Switching From TDF to TAF in Adults With Chronic Hepatitis B Who Are Virologically Suppressed

A Phase 3 study of Chronic Hepatitis B, sponsored by Gilead Sciences.

Completed
Registry status
Phase 3
Development phase
490
Enrollment target
20
Study locations

NCT02979613 is a Phase 3 study of Chronic Hepatitis B that has completed, run by Gilead Sciences. The registered enrollment target is 490 participants, above the 259-participant average among 14 other Chronic Hepatitis B trials with a reported enrollment target (89% higher). The trial reports 20 study locations across 9 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02979613, a Phase 3 study of Chronic Hepatitis B, has completed, sponsored by Gilead Sciences.

COMPLETED
Registry status
Phase 3
Development phase
490 participants
Enrollment target
20
Study locations

Study Summary

The primary objectives of this study are to evaluate the efficacy, safety, and tolerability of switching to tenofovir alafenamide (TAF) versus continuing tenofovir disoproxil fumarate (TDF) in virologically suppressed adults with chronic hepatitis B virus (HBV) infection.

Conditions Studied

Chronic Hepatitis B

Interventions

  • DRUG TAF
  • DRUG TDF
  • DRUG TDF Placebo
  • DRUG TAF Placebo

Study Locations (20)

California

  • - Los Angeles
  • - Palo Alto
  • - Pasadena
  • - San Diego
  • - San Francisco
  • - San Jose

New York

  • - Flushing
  • - Flushing
  • - New York
  • - New York

Other

  • - Edmonton
  • - Toronto
  • - Vancouver

Pennsylvania

  • - Philadelphia
  • - Philadelphia

Maryland

  • - Baltimore

Massachusetts

  • - Boston

Michigan

  • - Novi

Tennessee

  • - Nashville

Trial Details

FieldValue
Enrollment Target 490 participants
Start Date 2016-12-29
Est. Completion 2020-01-30
Phase Phase 3

Sponsor

Gilead Sciences

504 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT02979613

The ClinicalTrials.gov registry entry for NCT02979613 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 490 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 259-participant average among 14 other Chronic Hepatitis B trials with a reported enrollment target (89% higher). The listed sponsor is Gilead Sciences, which has 504 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Chronic Hepatitis B appearing as the primary indexed condition, and to 4 interventions - of which TAF is the first listed.

NCT02979613 reports 20 study locations spanning 9 distinct geographic areas - top geographies include California, New York, Other.

Frequently Asked Questions

What is clinical trial NCT02979613 about?

NCT02979613 is a clinical study titled "Study to Evaluate Efficacy and Safety of Switching From TDF to TAF in Adults With Chronic Hepatitis B Who Are Virologically Suppressed". The primary objectives of this study are to evaluate the efficacy, safety, and tolerability of switching to tenofovir alafenamide (TAF) versus continuing tenofovir disoproxil fumarate (TDF) in virologically suppressed adults with chronic hepatitis B virus (HBV) infection.

What is the current status of trial NCT02979613?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 490 participants. The study started on 2016-12-29. Estimated completion is 2020-01-30.

What conditions does trial NCT02979613 study?

This clinical trial studies the following conditions: Chronic Hepatitis B.

What interventions are being tested in trial NCT02979613?

The interventions under investigation include: TAF (DRUG), TDF (DRUG), TDF Placebo (DRUG), TAF Placebo (DRUG).

Who is sponsoring clinical trial NCT02979613?

This trial is sponsored by Gilead Sciences, which has 504 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02979613 being conducted?

This trial has 20 study locations across California, Maryland, Massachusetts, Michigan, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Chronic Hepatitis B

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Chronic Hepatitis B

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.